Cargando…

Lymphocyte reconstitution following autologous stem cell transplantation for progressive MS

BACKGROUND: Autologous stem cell transplantation (ASCT) for progressive multiple sclerosis (MS) may reset the immune repertoire. OBJECTIVE: The objective of this paper is to analyse lymphocyte recovery in patients with progressive MS treated with ASCT. METHODS: Patients with progressive MS not respo...

Descripción completa

Detalles Bibliográficos
Autores principales: Cull, G, Hall, D, Fabis-Pedrini, MJ, Carroll, WM, Forster, L, Robins, F, Ghassemifar, R, Crosbie, C, Walters, S, James, I, Augustson, B, Kermode, AK
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5415040/
https://www.ncbi.nlm.nih.gov/pubmed/28607754
http://dx.doi.org/10.1177/2055217317700167
_version_ 1783233456145170432
author Cull, G
Hall, D
Fabis-Pedrini, MJ
Carroll, WM
Forster, L
Robins, F
Ghassemifar, R
Crosbie, C
Walters, S
James, I
Augustson, B
Kermode, AK
author_facet Cull, G
Hall, D
Fabis-Pedrini, MJ
Carroll, WM
Forster, L
Robins, F
Ghassemifar, R
Crosbie, C
Walters, S
James, I
Augustson, B
Kermode, AK
author_sort Cull, G
collection PubMed
description BACKGROUND: Autologous stem cell transplantation (ASCT) for progressive multiple sclerosis (MS) may reset the immune repertoire. OBJECTIVE: The objective of this paper is to analyse lymphocyte recovery in patients with progressive MS treated with ASCT. METHODS: Patients with progressive MS not responding to conventional treatment underwent ASCT following conditioning with high-dose cyclophosphamide and antithymocyte globulin. Lymphocyte subset analysis was performed before ASCT and for two years following ASCT. Neurological function was assessed by the EDSS before ASCT and for three years post-ASCT. RESULTS: CD4+ T-cells fell significantly post-transplant and did not return to baseline levels. Recent thymic emigrants and naïve T-cells fell sharply post-transplant but returned to baseline by nine months and twelve months, respectively. T-regulatory cells declined post-transplant and did not return to baseline levels. Th1 and Th2 cells did not change significantly while Th17 cells fell post-transplant but recovered to baseline by six months. Neurological function remained stable in the majority of patients. Progression-free survival was 69% at three years. CONCLUSION: This study demonstrates major changes in the composition of lymphocyte subsets following ASCT for progressive MS. In particular, ablation and subsequent recovery of thymic output is consistent with the concept that ASCT can reset the immune repertoire in MS patients.
format Online
Article
Text
id pubmed-5415040
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-54150402017-06-12 Lymphocyte reconstitution following autologous stem cell transplantation for progressive MS Cull, G Hall, D Fabis-Pedrini, MJ Carroll, WM Forster, L Robins, F Ghassemifar, R Crosbie, C Walters, S James, I Augustson, B Kermode, AK Mult Scler J Exp Transl Clin Original Article BACKGROUND: Autologous stem cell transplantation (ASCT) for progressive multiple sclerosis (MS) may reset the immune repertoire. OBJECTIVE: The objective of this paper is to analyse lymphocyte recovery in patients with progressive MS treated with ASCT. METHODS: Patients with progressive MS not responding to conventional treatment underwent ASCT following conditioning with high-dose cyclophosphamide and antithymocyte globulin. Lymphocyte subset analysis was performed before ASCT and for two years following ASCT. Neurological function was assessed by the EDSS before ASCT and for three years post-ASCT. RESULTS: CD4+ T-cells fell significantly post-transplant and did not return to baseline levels. Recent thymic emigrants and naïve T-cells fell sharply post-transplant but returned to baseline by nine months and twelve months, respectively. T-regulatory cells declined post-transplant and did not return to baseline levels. Th1 and Th2 cells did not change significantly while Th17 cells fell post-transplant but recovered to baseline by six months. Neurological function remained stable in the majority of patients. Progression-free survival was 69% at three years. CONCLUSION: This study demonstrates major changes in the composition of lymphocyte subsets following ASCT for progressive MS. In particular, ablation and subsequent recovery of thymic output is consistent with the concept that ASCT can reset the immune repertoire in MS patients. SAGE Publications 2017-03-23 /pmc/articles/PMC5415040/ /pubmed/28607754 http://dx.doi.org/10.1177/2055217317700167 Text en © The Author(s) 2017 http://creativecommons.org/licenses/by-nc/3.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License (http://www.creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Article
Cull, G
Hall, D
Fabis-Pedrini, MJ
Carroll, WM
Forster, L
Robins, F
Ghassemifar, R
Crosbie, C
Walters, S
James, I
Augustson, B
Kermode, AK
Lymphocyte reconstitution following autologous stem cell transplantation for progressive MS
title Lymphocyte reconstitution following autologous stem cell transplantation for progressive MS
title_full Lymphocyte reconstitution following autologous stem cell transplantation for progressive MS
title_fullStr Lymphocyte reconstitution following autologous stem cell transplantation for progressive MS
title_full_unstemmed Lymphocyte reconstitution following autologous stem cell transplantation for progressive MS
title_short Lymphocyte reconstitution following autologous stem cell transplantation for progressive MS
title_sort lymphocyte reconstitution following autologous stem cell transplantation for progressive ms
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5415040/
https://www.ncbi.nlm.nih.gov/pubmed/28607754
http://dx.doi.org/10.1177/2055217317700167
work_keys_str_mv AT cullg lymphocytereconstitutionfollowingautologousstemcelltransplantationforprogressivems
AT halld lymphocytereconstitutionfollowingautologousstemcelltransplantationforprogressivems
AT fabispedrinimj lymphocytereconstitutionfollowingautologousstemcelltransplantationforprogressivems
AT carrollwm lymphocytereconstitutionfollowingautologousstemcelltransplantationforprogressivems
AT forsterl lymphocytereconstitutionfollowingautologousstemcelltransplantationforprogressivems
AT robinsf lymphocytereconstitutionfollowingautologousstemcelltransplantationforprogressivems
AT ghassemifarr lymphocytereconstitutionfollowingautologousstemcelltransplantationforprogressivems
AT crosbiec lymphocytereconstitutionfollowingautologousstemcelltransplantationforprogressivems
AT walterss lymphocytereconstitutionfollowingautologousstemcelltransplantationforprogressivems
AT jamesi lymphocytereconstitutionfollowingautologousstemcelltransplantationforprogressivems
AT augustsonb lymphocytereconstitutionfollowingautologousstemcelltransplantationforprogressivems
AT kermodeak lymphocytereconstitutionfollowingautologousstemcelltransplantationforprogressivems